Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NovoCure LtdNVCR · Entity 4494 | Chief Medical Officer | January 06, 2023 | January 10, 2023 |
| Opus Genetics, Inc.RNN · Entity 5892 | Chief Medical Officer | February 28, 2019 | March 01, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NovoCure Ltd
Report date January 06, 2023 · Filed January 10, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 28,770 |
Reported balance
After 2023-01-06 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-01-06 · Grant · Acquired 98 · Balance 28,770 F1: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2022 through December 30, 2022. This transaction is also exempt under Rule 16b-3(c). F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on July 1, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2022 through December 30, 2022. This transaction is also exempt under Rule 16b-3(c).
F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on July 1, 2022.
Opus Genetics, Inc.
Report date February 28, 2019 · Filed March 01, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,750 |
Reported balance
After 2019-02-28 transaction · row 1
1 source rowRow 1 · 2019-02-28 · Exercise / conversion · Acquired 2,375 · Balance 4,750 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 4,750 |
Reported balance
After 2019-02-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-02-28 · Exercise / conversion · Disposed 2,375 · Balance 4,750 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock. F2: On January 20, 2017, the reporting person was granted 9,500 RSUs, of which 2,375 vested on February 28, 2018 and 2,375 vested on February 28, 2019. The remaining RSUs will vest in two equal annual installments on the last business day in February, beginning February 28, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock.
F2: On January 20, 2017, the reporting person was granted 9,500 RSUs, of which 2,375 vested on February 28, 2018 and 2,375 vested on February 28, 2019. The remaining RSUs will vest in two equal annual installments on the last business day in February, beginning February 28, 2020.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 06, 2023 Filed Jan 10, 2023 21:14 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 98 | $62.31 | $6,105.89 |
DisclosureSEC source: 0001645113-23-000012 · wf-form4_167338526960077.xml · nonDerivative · entry 1 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,770 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2022 through December 30, 2022. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on July 1, 2022. Read SEC document |
| August 03, 2022 Filed Aug 4, 2022 20:32 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 5,396 | $74.00 | $399,304.00 |
DisclosureSEC source: 0001645113-22-000073 · wf-form4_165964508670843.xml · nonDerivative · entry 2 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,672 Read SEC document |
| August 03, 2022 Filed Aug 4, 2022 20:32 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 563 | $71.09 | $40,023.67 |
DisclosureSEC source: 0001645113-22-000073 · wf-form4_165964508670843.xml · nonDerivative · entry 1 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,068 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Dr. Benaim. Read SEC document |
| August 02, 2022 Filed Aug 3, 2022 20:44 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 437 | $69.66 | $30,440.98 |
DisclosureSEC source: 0001645113-22-000070 · wf-form4_165955944560794.xml · nonDerivative · entry 1 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,631 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| July 05, 2022 Filed Jul 7, 2022 21:47 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 222 | $59.08 | $13,114.65 |
DisclosureSEC source: 0001645113-22-000061 · wf-form4_165723043635515.xml · nonDerivative · entry 1 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,068 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2022 through June 30, 2022. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2022. Read SEC document |
| May 11, 2022 Filed May 12, 2022 20:30 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,135 | $61.25 | $130,768.75 |
DisclosureSEC source: 0001645113-22-000046 · wf-form4_165238737966787.xml · nonDerivative · entry 2 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,846 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| May 10, 2022 Filed May 12, 2022 20:30 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,070 | $65.16 | $134,877.06 |
DisclosureSEC source: 0001645113-22-000046 · wf-form4_165238737966787.xml · nonDerivative · entry 1 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,981 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Amended total to correct prior mathematical error. Read SEC document |
| March 04, 2022 Filed Mar 7, 2022 23:18 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,510 | $70.41 | $106,314.57 |
DisclosureSEC source: 0001645113-22-000017 · wf-form4_164669511463233.xml · nonDerivative · entry 3 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,257 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 23:18 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 5,452 | $80.59 Strike: $80.59 | $439,376.68 |
DisclosureSEC source: 0001645113-22-000017 · wf-form4_164669511463233.xml · derivative · entry 5 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,452 Underlying: Ordinary Shares · 5,452 shares Expires 2032-02-29 F4 · shares: Options to buy 5,452 ordinary shares will vest and become exercisable in equal installments on each of March 1, 2023 and 2024, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 23:18 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 30,422 | $80.59 Strike: $80.59 | $2,451,708.98 |
DisclosureSEC source: 0001645113-22-000017 · wf-form4_164669511463233.xml · derivative · entry 4 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,422 Underlying: Ordinary Shares · 30,422 shares Expires 2032-02-29 F3 · shares: Options to buy 30,422 ordinary shares will vest and become exercisable in equal installments on each of March 1, 2023, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 23:18 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 803 | $74.50 | $59,821.89 |
DisclosureSEC source: 0001645113-22-000017 · wf-form4_164669511463233.xml · nonDerivative · entry 2 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,767 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 23:18 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 17,371 | $0.00 | $0.00 |
DisclosureSEC source: 0001645113-22-000017 · wf-form4_164669511463233.xml · nonDerivative · entry 1 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,570 F1 · shares: Represents restricted share units that are scheduled to vest in equal installments on March 1, 2023, 2024 and 2025, subject to the reporting person's continued employment through such dates. Read SEC document |
| January 06, 2022 Filed Jan 12, 2022 22:38 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 55 | $63.82 | $3,509.99 |
DisclosureSEC source: 0001645113-22-000006 · wf-form4_164202710572487.xml · nonDerivative · entry 1 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,199 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2021 through December 31, 2021. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on December 31, 2021. Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 20:59 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 464 | $150.11 | $69,651.04 |
DisclosureSEC source: 0001645113-21-000095 · wf-form4_162811071615273.xml · nonDerivative · entry 1 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,144 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Dr. Benaim. Read SEC document |
| August 02, 2021 Filed Aug 3, 2021 21:29 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 536 | $149.38 | $80,066.61 |
DisclosureSEC source: 0001645113-21-000094 · wf-form4_162802611472815.xml · nonDerivative · entry 3 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,608 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| July 30, 2021 Filed Aug 3, 2021 21:29 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 651 | $0.00 Strike: $83.30 | $0.00 |
DisclosureSEC source: 0001645113-21-000094 · wf-form4_162802611472815.xml · derivative · entry 4 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,253 Underlying: Ordinary Shares · 651 shares Expires 2029-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| July 30, 2021 Filed Aug 3, 2021 21:29 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 651 | $158.96 | $103,482.96 |
DisclosureSEC source: 0001645113-21-000094 · wf-form4_162802611472815.xml · nonDerivative · entry 2 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,144 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Dr. Benaim. Read SEC document |
| July 30, 2021 Filed Aug 3, 2021 21:29 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 651 | $83.30 | $54,228.30 |
DisclosureSEC source: 0001645113-21-000094 · wf-form4_162802611472815.xml · nonDerivative · entry 1 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,795 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Dr. Benaim. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 21:32 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 90 | $137.12 | $12,340.98 |
DisclosureSEC source: 0001645113-21-000085 · wf-form4_162577994550029.xml · nonDerivative · entry 1 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,144 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2021 through June 30, 2021. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2021. Read SEC document |
| May 27, 2021 Filed May 28, 2021 20:36 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 1,833 | $0.00 Strike: $47.56 | $0.00 |
DisclosureSEC source: 0001645113-21-000069 · wf-form4_162223413522679.xml · derivative · entry 3 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,332 Underlying: Ordinary Shares · 1,833 shares Expires 2029-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| May 27, 2021 Filed May 28, 2021 20:36 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,833 | $200.00 | $366,600.00 |
DisclosureSEC source: 0001645113-21-000069 · wf-form4_162223413522679.xml · nonDerivative · entry 2 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,054 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Dr. Benaim. Read SEC document |
| May 27, 2021 Filed May 28, 2021 20:36 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 1,833 | $47.56 | $87,177.48 |
DisclosureSEC source: 0001645113-21-000069 · wf-form4_162223413522679.xml · nonDerivative · entry 1 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,887 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 12, 2021 Filed May 14, 2021 20:07 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,943 | $180.48 | $350,672.64 |
DisclosureSEC source: 0001645113-21-000068 · wf-form4_162102283236308.xml · nonDerivative · entry 1 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,054 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Dr. Benaim. Read SEC document |
| May 11, 2021 Filed May 12, 2021 20:15 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,262 | $180.12 | $407,426.92 |
DisclosureSEC source: 0001645113-21-000067 · wf-form4_162085051621853.xml · nonDerivative · entry 3 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,997 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| May 10, 2021 Filed May 12, 2021 20:15 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 1,833 | $0.00 Strike: $47.56 | $0.00 |
DisclosureSEC source: 0001645113-21-000067 · wf-form4_162085051621853.xml · derivative · entry 4 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,165 Underlying: Ordinary Shares · 1,833 shares Expires 2029-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| May 10, 2021 Filed May 12, 2021 20:15 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,833 | $189.65 | $347,628.45 |
DisclosureSEC source: 0001645113-21-000067 · wf-form4_162085051621853.xml · nonDerivative · entry 2 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,259 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Dr. Benaim. Read SEC document |
| May 10, 2021 Filed May 12, 2021 20:15 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 1,833 | $47.56 | $87,177.48 |
DisclosureSEC source: 0001645113-21-000067 · wf-form4_162085051621853.xml · nonDerivative · entry 1 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,092 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 21:59 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 3,474 | $0.00 Strike: $69.37 | $0.00 |
DisclosureSEC source: 0001645113-21-000053 · wf-form4_161852392575490.xml · derivative · entry 9 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,404 Underlying: Ordinary Shares · 3,474 shares Expires 2030-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 21:59 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 651 | $0.00 Strike: $83.30 | $0.00 |
DisclosureSEC source: 0001645113-21-000053 · wf-form4_161852392575490.xml · derivative · entry 8 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,904 Underlying: Ordinary Shares · 651 shares Expires 2029-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 21:59 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 1,833 | $0.00 Strike: $47.56 | $0.00 |
DisclosureSEC source: 0001645113-21-000053 · wf-form4_161852392575490.xml · derivative · entry 7 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,998 Underlying: Ordinary Shares · 1,833 shares Expires 2029-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 21:59 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 3,474 | $200.00 | $694,800.00 |
DisclosureSEC source: 0001645113-21-000053 · wf-form4_161852392575490.xml · nonDerivative · entry 6 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,259 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Dr. Benaim. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 21:59 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 3,474 | $69.37 | $240,991.38 |
DisclosureSEC source: 0001645113-21-000053 · wf-form4_161852392575490.xml · nonDerivative · entry 5 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,733 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 21:59 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 651 | $200.00 | $130,200.00 |
DisclosureSEC source: 0001645113-21-000053 · wf-form4_161852392575490.xml · nonDerivative · entry 4 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,259 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Dr. Benaim. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 21:59 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 651 | $83.30 | $54,228.30 |
DisclosureSEC source: 0001645113-21-000053 · wf-form4_161852392575490.xml · nonDerivative · entry 3 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,910 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 21:59 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,833 | $200.00 | $366,600.00 |
DisclosureSEC source: 0001645113-21-000053 · wf-form4_161852392575490.xml · nonDerivative · entry 2 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,259 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Dr. Benaim. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 21:59 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 1,833 | $47.56 | $87,177.48 |
DisclosureSEC source: 0001645113-21-000053 · wf-form4_161852392575490.xml · nonDerivative · entry 1 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,092 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 05, 2021 Filed Mar 9, 2021 21:16 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,918 | $131.53 | $383,804.54 |
DisclosureSEC source: 0001645113-21-000041 · wf-form4_161532454290586.xml · nonDerivative · entry 1 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,259 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Dr. Benaim. Read SEC document |
| March 04, 2021 Filed Mar 5, 2021 22:44 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleRestricted Share Units | 1,888 | $137.55 | $259,701.95 |
DisclosureSEC source: 0001645113-21-000036 · wf-form4_161498426934871.xml · nonDerivative · entry 3 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,177 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units vested on March 3, 2021. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 03, 2021 Filed Mar 5, 2021 22:44 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 3,475 | $0.00 Strike: $69.37 | $0.00 |
DisclosureSEC source: 0001645113-21-000036 · wf-form4_161498426934871.xml · derivative · entry 4 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,878 Underlying: Ordinary Shares · 3,475 shares Expires 2030-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| March 03, 2021 Filed Mar 5, 2021 22:44 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 3,475 | $150.78 | $523,960.50 |
DisclosureSEC source: 0001645113-21-000036 · wf-form4_161498426934871.xml · nonDerivative · entry 2 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,065 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Dr. Benaim. Read SEC document |
| March 03, 2021 Filed Mar 5, 2021 22:44 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 3,475 | $69.37 | $241,060.75 |
DisclosureSEC source: 0001645113-21-000036 · wf-form4_161498426934871.xml · nonDerivative · entry 1 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,540 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 22:53 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 16,003 | $0.00 Strike: $153.09 | $0.00 |
DisclosureSEC source: 0001645113-21-000031 · wf-form4_161489839039798.xml · derivative · entry 2 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,003 Underlying: Ordinary Shares · 16,003 shares Expires 2031-03-01 F2 · derivative.exercise_date: Options to buy 16,003 ordinary shares will vest and become exercisable in equal installments on each of March 2, 2022, 2023, 2024 and 2025, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 22:53 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantRestricted Share Units | 8,709 | $0.00 | $0.00 |
DisclosureSEC source: 0001645113-21-000031 · wf-form4_161489839039798.xml · nonDerivative · entry 1 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,065 F1 · shares: Represents restricted share units that are scheduled to vest in equal installments on each of March 2, 2022, 2023 and 2024, subject to the reporting person's continued employment through such dates. Read SEC document |
| December 21, 2020 Filed Dec 22, 2020 23:39 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 651 | $0.00 Strike: $83.30 | $0.00 |
DisclosureSEC source: 0001628280-20-017712 · wf-form4_160868035486570.xml · derivative · entry 6 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,555 Underlying: Ordinary Shares · 651 shares Expires 2029-07-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| December 21, 2020 Filed Dec 22, 2020 23:39 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 1,833 | $0.00 Strike: $47.56 | $0.00 |
DisclosureSEC source: 0001628280-20-017712 · wf-form4_160868035486570.xml · derivative · entry 5 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,831 Underlying: Ordinary Shares · 1,833 shares Expires 2029-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| December 21, 2020 Filed Dec 22, 2020 23:39 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 651 | $156.71 | $102,018.21 |
DisclosureSEC source: 0001628280-20-017712 · wf-form4_160868035486570.xml · nonDerivative · entry 4 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,356 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Dr. Benaim. Read SEC document |
| December 21, 2020 Filed Dec 22, 2020 23:39 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 651 | $83.30 | $54,228.30 |
DisclosureSEC source: 0001628280-20-017712 · wf-form4_160868035486570.xml · nonDerivative · entry 3 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,007 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 21, 2020 Filed Dec 22, 2020 23:39 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,833 | $156.71 | $287,249.43 |
DisclosureSEC source: 0001628280-20-017712 · wf-form4_160868035486570.xml · nonDerivative · entry 2 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,356 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Dr. Benaim. Read SEC document |
| December 21, 2020 Filed Dec 22, 2020 23:39 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 1,833 | $47.56 | $87,177.48 |
DisclosureSEC source: 0001628280-20-017712 · wf-form4_160868035486570.xml · nonDerivative · entry 1 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,189 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 20:11 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 660 | $76.06 | $50,199.60 |
DisclosureSEC source: 0001645113-20-000115 · wf-form4_159665826501157.xml · nonDerivative · entry 1 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,356 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Dr. Benaim. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.